References in periodicals archive ?
Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women.
The patent protecting the dosing regimen of administering 60 mg/day Raloxifene hydrochloride in the treatment and prevention of osteoporosis is considered to further constrain generic entry until March 2014.
Raloxifene hydrochloride is the active ingredient in Evista[R], Eli Lilly's immediate release tablets for osteoporosis.
Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet.
Raloxifene hydrochloride is the active ingredient in Evista(R), Eli Lilly's immediate release tablets for osteoporosis.
Raloxifene hydrochloride is the active ingredient in Evista(R), Eli Lilly and Company's immediate release tablets for osteoporosis.
In addition to CDT-based raloxifene hydrochloride, we also previously announced that we are initiating development of a CDT-based ondansetron hydrochloride formulation.
Barr filed an ANDA for Raloxifene Hydrochloride 60 mg tablets with the U.